David Roofeh1, Dinesh Khanna. 1. Department of Internal Medicine, Division of Rheumatology, Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA.
Abstract
PURPOSE OF REVIEW: This review provides a risk-stratified and evidence-based management for subsets of systemic sclerosis (SSc) patients in the first five years from disease onset. RECENT FINDINGS: Cardiopulmonary disease remains the primary cause of mortality in SSc patients. Morbidity and mortality in SSc-associated pulmonary arterial hypertension have improved with combination treatment, in either an upfront or sequential treatment pattern. Traditional therapies for interstitial lung disease (SSc-ILD) have targeted those with clinically significant and progressive ILD with immunosuppression. New data suggest a possible paradigm shift, introducing immunosuppressive therapy to patients before they develop clinically significant or progressive ILD. The year 2019 saw the approval of the first FDA-approved therapy for SSc-associated interstitial lung disease, using an antifibrotic agent previously approved for idiopathic pulmonary fibrosis. To date, only autologous hematopoietic stem cell transplant has demonstrated a mortality benefit for SSc-ILD, albeit in a narrow spectrum of SSc-ILD patients. SUMMARY: SSc is a highly heterogeneous autoimmune disease typified by varying clinical trajectories. Its management may be stratified within the first five years by subclassifying patients based on factors that have important prognostic significance: skin distribution and autoantibody status.
PURPOSE OF REVIEW: This review provides a risk-stratified and evidence-based management for subsets of systemic sclerosis (SSc) patients in the first five years from disease onset. RECENT FINDINGS: Cardiopulmonary disease remains the primary cause of mortality in SSc patients. Morbidity and mortality in SSc-associated pulmonary arterial hypertension have improved with combination treatment, in either an upfront or sequential treatment pattern. Traditional therapies for interstitial lung disease (SSc-ILD) have targeted those with clinically significant and progressive ILD with immunosuppression. New data suggest a possible paradigm shift, introducing immunosuppressive therapy to patients before they develop clinically significant or progressive ILD. The year 2019 saw the approval of the first FDA-approved therapy for SSc-associated interstitial lung disease, using an antifibrotic agent previously approved for idiopathic pulmonary fibrosis. To date, only autologous hematopoietic stem cell transplant has demonstrated a mortality benefit for SSc-ILD, albeit in a narrow spectrum of SSc-ILD patients. SUMMARY: SSc is a highly heterogeneous autoimmune disease typified by varying clinical trajectories. Its management may be stratified within the first five years by subclassifying patients based on factors that have important prognostic significance: skin distribution and autoantibody status.
Authors: John A Mackintosh; Anna Stainer; Joseph L Barnett; Elisabetta A Renzoni Journal: Semin Respir Crit Care Med Date: 2019-05-28 Impact factor: 3.119
Authors: Dinesh Khanna; Chi-Hong Tseng; Niloofar Farmani; Virginia Steen; Daniel E Furst; Philip J Clements; Michael D Roth; Jonathan Goldin; Robert Elashoff; James R Seibold; Rajeev Saggar; Donald P Tashkin Journal: Arthritis Rheum Date: 2011-10
Authors: George Hung; Valentina Mercurio; Steven Hsu; Stephen C Mathai; Ami A Shah; Monica Mukherjee Journal: Curr Rheumatol Rep Date: 2019-12-07 Impact factor: 4.592
Authors: Jerome Avouac; Ulrich Walker; Alan Tyndall; André Kahan; Marco Matucci-Cerinic; Yannick Allanore; I Miniati; A Muller; F Iannone; O Distler; R Becvar; S Sierakowsky; O Kowal-Bielecka; P Coelho; J Cabane; M Cutolo; Y Shoenfeld; G Valentini; J Rovensky; G Riemekasten; P Vlachoyiannopoulos; R Caporali; S Jiri; M Inanc; I Zimmermann Gorska; P Carreira; S Novak; L Czirjak; F Oliveira Ramos; M Jendro; C Chizzolini; E J Kucharz; J Richter; F Cozzi; B Rozman; C M Mallia; A Gabrielli; D Farge; H P Kiener; D Schöffel; P Airo; F Wollheim; D Martinovic; F Trotta; S Jablonska; K Reich; S Bombardieri; P Siakka; R Pellerito; L M Bambara; J Morovic-Vergles; C Denton; R Hinrichs; F Van den Hoogen; N Damjanov; I Kötter; V Ortiz; S Heitmann; D Krasowska; M Seidel; P Hasler; J M Van Laar; J P Kaltwasser; I Foeldvari; A Juan Mas; G Bajocchi; M Wislowska; J A Pereira Da Silva; S Jacobsen; M Worm; W Graniger; A Kuhn; A Stankovic; R Cossutta; M Majdan; L Damjanovska Rajcevska; M Tikly; E L Nasonov; K Steinbrink; A Herrick; U Müller-Ladner; A Dinc; R Scorza; K Sondergaard; F Indiveri; H Nielsen; Z Szekanecz; R M Silver; M Antivalle; I B Espinosa; P García de la Pena Lefebvre; O Midtvedt; D Launay; F Valesini; P Tuvik; R M Ionescu; N Del Papa; S Pinto; F Wigley; C Mihai; M Sinziana Capranu; C Sunderkötter; J B Jun; S Alhasani; J H Distler; E Ton; T Soukup; J Seibold; S Zeni; P Nash; L Mouthon; F De Keyser; M T Duruöz; F P Cantatore; G Strauss; C A von Mülhen; M R Pozzi; K Eyerich; J Szechinski; M Keiserman; F A Houssiau; J A Román-Ivorra; B Krummel-Lorenz; M Aringer; R Westhovens; F Bellisai; M Mayer; F Stoeckl; M Uprus; A Volpe; M Buslau; S Yavuz; B Granel; A Valderílio Feijó; F Del Galdo; S Popa; T Zenone; X Ricardo Machado; M Pileckyte; S Stebbings; A Mathieu; A Tulli; T Tourinho; R Souza; R Acayaba de Toledo; L Stamp; K Solanki; D Veale; J Francisco Marques Neto; G F Bagnato; E Loyo; S Toloza; M Li; W Ahmed Abdel Atty Mohamed; V Cobankara; J Olas; F Salsano; F Oksel; C M Tanaseanu; R Foti; C Ancuta; M Vonk; P Caramashi; L Beretta; A Balbir; A Chiàla; K Pasalic Simic; M Ghio; B Stamenkovic; S Rednic; N Host; R Pellerito; E Hachulla; D E Furst Journal: J Rheumatol Date: 2010-06-15 Impact factor: 4.666
Authors: Shervin Assassi; Roozbeh Sharif; Robert E Lasky; Terry A McNearney; Rosa M Estrada-Y-Martin; Hilda Draeger; Deepthi K Nair; Marvin J Fritzler; John D Reveille; Frank C Arnett; Maureen D Mayes Journal: Arthritis Res Ther Date: 2010-09-02 Impact factor: 5.156
Authors: John Gerry Coghlan; Nazzareno Galiè; Joan Albert Barberà; Adaani E Frost; Hossein-Ardeschir Ghofrani; Marius M Hoeper; Masataka Kuwana; Vallerie V McLaughlin; Andrew J Peacock; Gérald Simonneau; Jean-Luc Vachiéry; Christiana Blair; Hunter Gillies; Karen L Miller; Julia H N Harris; Jonathan Langley; Lewis J Rubin Journal: Ann Rheum Dis Date: 2016-12-30 Impact factor: 19.103
Authors: David Roofeh; Celia J F Lin; Jonathan Goldin; Grace Hyun Kim; Daniel E Furst; Christopher P Denton; Suiyuan Huang; Dinesh Khanna Journal: Arthritis Rheumatol Date: 2021-05-25 Impact factor: 15.483
Authors: Dinesh Khanna; Alain Lescoat; David Roofeh; Elana J Bernstein; Ella A Kazerooni; Michael D Roth; Fernando Martinez; Kevin R Flaherty; Christopher P Denton Journal: Arthritis Rheumatol Date: 2021-11-10 Impact factor: 15.483